San Carlos, CA, United States of America

Emily Long

USPTO Granted Patents = 2 

Average Co-Inventor Count = 4.0

ph-index = 1


Company Filing History:


Years Active: 2022-2025

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Innovations by Emily Long in COVID-19 Treatment

Introduction

Emily Long is an accomplished inventor based in San Carlos, California. She has made significant contributions to the field of medical science, particularly in the treatment of COVID-19. With two patents to her name, her work focuses on innovative methods for diagnosing and treating chronic COVID-19 conditions.

Latest Patents

Emily Long's latest patents include groundbreaking methods for assigning a COVID pathological type based on a cytokine/chemokine panel. These methods provide a way to determine the COVID pathological type for subjects suffering from COVID-19 by analyzing a quantitative, multiplex cytokine/chemokine panel in test samples. Additionally, her patents outline methods for treating long-hauler subjects by administering a CCR5/CCL5 interaction inhibitor. These methods and compositions are designed for various applications, including patient stratification and therapy response assessment.

Career Highlights

Emily Long is currently associated with Incelldx, Inc., where she continues to develop her innovative ideas. Her work has been instrumental in advancing the understanding and treatment of COVID-19, particularly for those experiencing long-term effects of the virus.

Collaborations

Emily collaborates with notable professionals in her field, including Bruce K Patterson and Edgar B Francisco. Their combined expertise contributes to the development of effective treatments and methodologies in the fight against COVID-19.

Conclusion

Emily Long's contributions to the medical field, particularly in the context of COVID-19, highlight her innovative spirit and dedication to improving patient outcomes. Her patents represent a significant step forward in understanding and treating chronic COVID-19 conditions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…